Effectiveness of Phenazopyridine for Pain Following Urodynamics

University of South Florida

Status and phase: Enrolling; Phase 4

Conditions: Pain After Urodynamic Testing

Treatments: Drug: Phenazopyridine Hydrochloride 99.5 MG

Study type: Interventional

Funder types: Other

Identifiers

NCT06577493

007227

Details and patient eligibility

About

The purpose of the study is to determine if taking phenazopyridine (AZO) at the time of urodynamic study testing will decrease pain experienced by patients after undergoing urodynamic testing.

Enrollment: 66 estimated patients

Sex: Female

Ages: 18 to 99 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• ability to provide informed consent
• ability to complete visual analog scale
• requiring urodynamic testing
• 18 years of age or older
• must be able to read and write in English or Spanish

Exclusion criteria

• allergy to phenazopyridine
• a urinary tract infection in the prior 2 weeks
• women who did not undergo urodynamic testing
• patient less than 18 years old
• patients with known (noted in patient chart and verbally asked) severe renal insufficiency with GFR <50 mL/min,
• patients with known (noted in patient chart and verbally asked) severe hepatitis
• patients with known (noted in patient chart and verbally asked) G6PD deficiency
• history of fibromyalgia
• history of interstitial cystitis
• non English or Spanish speaking

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

66 participants in 2 patient groups

Experimental Arm

Experimental group

Description:

Patient to take two 99.5mg phenazopyridine hydrochloride (AZO) for a total of 199 mg by mouth once immediately prior to the start of urodynamic testing.

Treatment:

Drug: Phenazopyridine Hydrochloride 99.5 MG

Control Arm

No Intervention group

Description:

Patient to not receive any medication prior to the start of urodynamic testing.